Hélène Lê

Hélène Lê

Auto-generated profile, based on publicly available information

Hélène Lê

INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
JSJoseph Seitlinger
Joseph Seitlinger
ANanasse nounsi
anasse nounsi
YIYsia Idoux-Gillet
Ysia Idoux-Gillet
ESEloy Santos-Pujol
Eloy Santos-Pujol
HLHélène Lê
Hélène Lê
Nadia Benkirane-JesselNadia Benkirane-Jessel
Nadia Benkirane-Jessel
Patient-derived tumoroid (PDT) has been developed and used for anti-drug screening in the last decade. As compared to other existing drug screening models, a PDT-based in vitro 3D cell culture model could preserve the histological and mutational characteristics of their corresponding tumors and mimic the tumor microenvironment. However, few studies have been carried out to improve the microvascular network connecting the PDT and its surrounding microenvironment, knowing that poor tumor-selective drug transport and delivery is one of the major reasons for both the failure of anti-cancer drug screens and resistance in clinical treatment. In this study, we formed vascularized PDTs in six days using multiple cell types which maintain the histopathological features of the original cancer tissue. Furthermore, our results demonstrated a vascular network connecting PDT and its surrounding microenvironment. This fast and promising PDT model opens new perspectives for personalized medicine: this model could easily be used to test all therapeutic treatments and could be connected with a microfluidic device for more accurate drug screening.